Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Chipotle Mexican Grill, Inc. (CMG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Chipotle Mexican Grill, Inc. — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $224 (market cap $29.60B), while Chipotle Mexican Grill, Inc. trades at $32.66 (market cap $40.49B). The key difference: Chipotle Mexican Grill, Inc. is the larger of the two by market cap, and Chipotle Mexican Grill, Inc. is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | CMG | |
|---|---|---|
Market Cap | $29.60B | $40.49B |
Sector | Health | Consumer Cyclical |
52-Week High | $491.22 | $44.04 |
52-Week Low | $205.48 | $28.17 |
Enterprise Value | $27.56B | $45.24B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
Chipotle Mexican Grill (CMG) trades at $32.615, up 1.48% today, but faces headwinds from recent food safety concerns linked to salmonella outbreaks. The stock's technical outlook is bearish, with moving averages signaling selling pressure. Fundamentally, the company reported strong revenue growth to $11.93B in 2025 and a net income margin of 11.42%, though earnings face compression from rising costs. Recent news highlights ongoing litigation investigations and promotional efforts to boost customer engagement.
The investment outlook is mixed; analyst consensus remains bullish with a $42.17 price target, but near-term risks from food safety issues and margin pressures could limit upside. Long-term growth prospects are supported by consistent revenue increases, but investors should monitor resolution of health concerns and cost management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Chipotle Mexican Grill, Inc.
Chipotle Mexican Grill is the largest fast-casual chain restaurant in the United States, with systemwide sales of $7.5 billion in 2021. The Mexican concept is entirely company-owned, with a footprint of more than 3,000 stores, heavily indexed to the United States (though the firm maintains a small presence in Canada, the U.K., France, and Germany). Chipotle sells burritos, burrito bowls, tacos, quesadillas, and beverages, with a selling proposition built around competitive prices, high-quality food sourcing, speed of service, and convenience. The company generates its revenue entirely from restaurant sales and delivery fees.
Read more on CMG →
